NHS Launches Major GP Bonus Scheme for Weight Loss Drug Prescriptions
NHS England has unveiled a groundbreaking incentive programme that will offer GP surgeries substantial financial bonuses to increase prescriptions of the Mounjaro weight loss medication. This controversial initiative, set to begin in April 2026, represents a significant shift in how Britain approaches its escalating obesity crisis through pharmaceutical intervention.
Financial Incentives for General Practitioners
Under the new scheme, family doctors will be eligible to claim a one-off payment of up to £3,000 for every 1,000 patients registered at their local practice. Health officials have specifically designed these payments to cover the administrative costs associated with identifying and supporting eligible patients for Mounjaro treatment.
Health Secretary Wes Streeting has been vocal about his determination to ensure access to these medications is based on medical need rather than financial capability. "Weight loss drugs can be a real game changer for those who need them," Streeting stated. "I'm determined that access should be based on need, not ability to pay."
Current and Future Access Criteria
Mounjaro only began being prescribed by GPs during the current 2025-2026 financial year, with access currently restricted to severely obese individuals who have both a Body Mass Index (BMI) exceeding 40 and specific weight-related health conditions. To qualify under existing guidelines, patients must typically present with a high BMI alongside at least one weight-related condition such as diabetes, high blood pressure, or obstructive sleep apnoea.
The government plans to significantly expand access next year to include those with a BMI over 35. By 2028, projections suggest approximately 220,000 patients will be receiving Mounjaro through NHS prescriptions, representing a substantial increase from current levels.
Addressing the Obesity Crisis
Health authorities believe that broader access to these pharmaceutical interventions will dramatically reduce the long-term burden on healthcare services. More than one million people are currently estimated to be using weight loss medications across Britain, with approximately ninety percent paying for them privately outside the NHS system.
The government hopes to reach those most at risk of developing chronic diseases associated with excess weight. Early intervention with these injectable medications could potentially prevent thousands of heart attacks and strokes annually across the country, shifting the NHS focus from treatment to prevention.
Controversy and Medical Debate
The incentive scheme has sparked considerable debate within medical communities regarding the ethics of implementing "performance-related pay" for specific prescription practices. Some healthcare professionals have expressed concerns that financial incentives might overshadow holistic patient care or create a "postcode lottery" for medication access.
Additional concerns have been raised about global supply chain issues affecting these medications, which have experienced significant shortages due to soaring international demand. Streeting addressed these concerns directly, noting: "Outside the NHS, we've seen those who can spare the cash buying privately, and the proliferation of rogue prescribers peddling dangerous unlicensed drugs that are putting patients at risk."
Comparison with Other Treatments
It's important to note that Wegovy, another new slimming medication available through the NHS, follows a different prescription pathway. Unlike Mounjaro, which GPs can prescribe directly, Wegovy must be supplied through specialist NHS weight loss services, creating distinct access channels for these pharmaceutical interventions.
The government's substantial investment in general practice through this bonus scheme aims to bring modern weight loss medicine to broader populations, potentially transforming how the healthcare system addresses one of Britain's most pressing public health challenges.
